Clinical Trials Browser

Phase 2 × Gliosarcoma × 90 days × Clear all

NCT04817254 2026-03-18

Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

Phase 2 Active not recruiting

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

NCT02455557 2026-02-25

SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

Phase 2 Active not recruiting

66 enrolled 11 charts

Glioblastoma, Gliosarcoma

NCT07301268 2026-02-03

GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma

Phase 2 Suspended

Astrocytoma, Glioblastoma, Gliosarcoma

NCT05465954 2026-01-12

Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma

Phase 2 Recruiting

Glioblastoma, Gliosarcoma